$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Bio-Techne beat Q4 FY2025 expectations and divested Exosome Diagnostics, but faces ongoing margin pressures and cautious customer spending amid high valuation.

# Bio-Techne Delivers Solid Q4 FY2025 Beat Amid Margin Pressures and Strategic Portfolio Shift

---

## Executive Summary

- **Bio-Techne (Q4 FY2025) delivered a modest beat on both revenue and adjusted EPS**, reporting **$316.96M in revenue** (vs. $316.00M consensus) and **$0.53 in adjusted EPS** (vs. $0.50 consensus), with year-over-year growth of 3.6% and 8.2% respectively. The beat was driven by **organic growth in core Protein Sciences** and a positive surprise in China, offsetting ongoing headwinds in customer spending.
- **Earnings quality was mixed**: while adjusted results were solid, **GAAP operating margin fell sharply to (7.5%)** due to an $83.1M impairment charge related to Exosome Diagnostics. Adjusted operating margin also compressed to 32.0% from 33.5% YoY, reflecting both one-off and underlying cost pressures.
- **Management struck a cautious but constructive tone**, citing continued customer conservatism and funding headwinds, but also highlighting the immediate margin benefits from the Exosome Diagnostics divestiture and resilience in international markets.
- **Key risks remain**: persistent funding constraints in biotech and academia, macroeconomic and tariff uncertainties, and ongoing margin pressures in Diagnostics & Spatial Biology. However, **upside exists in the form of margin expansion** from portfolio reshaping and stronger-than-expected growth in China.
- **Catalyst watch**: Near-term, the market is likely to react positively to the earnings beat and strategic divestiture, but sustained upside will depend on evidence of margin improvement and stabilization in core end markets.

---

## Performance Snapshot

| Metric                | Reported   | Consensus | Surprise | YoY Change |
|-----------------------|------------|-----------|----------|------------|
| Revenue               | $316.96M   | $316.00M  | +$0.96M  | +3.6%      |
| Adjusted EPS          | $0.53      | $0.50     | +$0.03   | +8.2%      |
| GAAP Operating Margin | (7.5%)     | —         | —        | -22.5pp    |
| Adj. Operating Margin | 32.0%      | —         | —        | -1.5pp     |
| Protein Sciences Rev. | $226.5M    | —         | —        | +6.0%      |
| Diagnostics & Spatial | —          | —         | —        | Margin ↓   |

---

## Earnings Quality

- **Revenue growth was primarily organic**, with Protein Sciences up 6% YoY, indicating healthy demand in core segments. There was no evidence of material one-offs (aside from the impairment) distorting top-line results.
- **Margin quality was mixed**: Adjusted operating margin compressed to 32.0% (from 33.5% YoY), while GAAP margin was deeply negative due to the Exosome Diagnostics impairment. Diagnostics & Spatial Biology segment margins also declined, suggesting some cost management challenges.
- **Cost structure**: While detailed breakdowns were not provided, the impairment and segment margin compression point to both one-off and ongoing cost pressures, particularly in Diagnostics.

---

## Management Commentary & Guidance

- **Management’s tone was cautious**, noting that customer spending is even more conservative than anticipated, and that funding headwinds are likely to persist in the near term.
- **Guidance was conservative but realistic**, calling for low single-digit organic growth and immediate margin improvement from the Exosome Diagnostics divestiture. Management emphasized ongoing cost productivity initiatives and a focus on core growth drivers.
- **Positive surprises** included stronger-than-expected growth in China and lower-than-anticipated NIH revenue exposure, reducing regulatory risk.

---

## Key Risks

- **Persistent funding constraints** in small biotech and academic research could continue to weigh on demand.
- **Margin pressures** in Diagnostics & Spatial Biology, as well as potential cost inflation, remain concerns.
- **Macro and regulatory risks**: Tariff uncertainties and global economic pressures could impact international performance.

---

## Expected Market Reaction

- **Analyst and investor sentiment is likely to be cautiously positive**: The earnings beat and strategic divestiture are expected to support the stock in the near term, as reflected in the initial post-earnings uptick.
- **Valuation remains a concern**: High multiples suggest the market is pricing in robust future growth, which may not materialize in the near term given management’s conservative outlook.

---

## Final Takeaway

- **Q4 FY2025 was a solid but not spectacular quarter for Bio-Techne**: The company delivered on adjusted metrics and took decisive action to improve margins, but underlying growth remains modest and margin pressures persist.
- **The market may be underestimating the near-term margin expansion potential** from the Exosome Diagnostics divestiture and the resilience in international markets, particularly China. However, high valuation multiples leave little room for disappointment if growth remains muted.
- **Upcoming catalysts**: Watch for evidence of margin improvement in the next quarter and any signs of stabilization or rebound in core end markets as funding conditions evolve. The closing of the Exosome Diagnostics sale and updates on China growth will also be key.

---

Bio-Techne: Margin Expansion Potential Post-Divestiture

Bio-Techne’s Q4 FY2025 beat on adjusted metrics, with portfolio reshaping and the Exosome Diagnostics divestiture driving margin strength despite GAAP losses from one-off charges.

# Bio-Techne Q4 FY2025: Portfolio Reshaping Drives Adjusted Margin Strength Despite GAAP Loss

---

## Executive Summary

- **Bio-Techne delivered a solid Q4 FY2025 on an adjusted basis, with revenue of $317.0M (+4% YoY) and adjusted EPS of $0.53, both exceeding consensus expectations.** However, GAAP results were impacted by significant one-off charges, resulting in an operating loss of $(23.9)M and GAAP EPS of $(0.11), a notable miss versus the prior year.
- **Margin quality remains robust on an adjusted basis** (adjusted operating margin at 32.0%), but GAAP margins were compressed by an $83.1M impairment and $13.2M in restructuring costs, primarily related to the divestiture of Exosome Diagnostics.
- **Management struck a cautiously optimistic tone,** emphasizing the strategic benefits of portfolio realignment and the expected immediate margin uplift from the Exosome Diagnostics sale. The company remains focused on high-growth, high-margin segments such as cell therapy and proteomic analytical instruments, while acknowledging ongoing macro and funding headwinds.
- **Risks include continued cost inflation, regulatory uncertainty, and potential volatility in academic and biotech funding.** However, the company’s retained rights to exosome-based technology and resilience in large pharma accounts present underappreciated upside.
- **Catalyst watch:** Near-term focus will be on the closing of the Exosome Diagnostics transaction, realization of margin improvements, and updates on capital allocation (notably share repurchases).

---

## Performance Snapshot

| Metric                | Reported   | Consensus | Surprise | YoY Change |
|-----------------------|------------|-----------|----------|------------|
| Revenue               | $317.0M    | $312.5M   | +1.4%    | +4%        |
| Adjusted EPS          | $0.53      | $0.51     | +3.9%    | +8%        |
| GAAP EPS              | $(0.11)    | $0.08     | -        | -          |
| GAAP Operating Margin | (7.5)%     | -         | -        | -22.5pp    |
| Adjusted Op Margin    | 32.0%      | -         | -        | -1.5pp     |
| Protein Sciences Rev  | +6% YoY    | -         | -        | +6%        |

---

## Earnings Quality

Bio-Techne’s Q4 revenue growth was driven by **organic volume and pricing strength in core segments**, particularly Protein Sciences (+6% YoY). **Adjusted gross and operating margins (70.0% and 32.0%, respectively) remain industry-leading**, though both saw modest YoY compression. The divergence between GAAP and adjusted profitability is explained by **non-recurring charges**: an $83.1M impairment (Exosome Diagnostics) and $13.2M in restructuring. Excluding these, underlying business fundamentals remain strong, with cost discipline and favorable product mix supporting adjusted margins.

---

## Management Commentary & Guidance

Management’s tone was **cautiously upbeat**, highlighting the strategic rationale for divesting Exosome Diagnostics and the expected **immediate margin uplift**. CEO Kim Kelderman emphasized a focus on high-growth, high-margin areas (cell therapy, proteomics, large pharma), while acknowledging persistent headwinds in academic and biotech funding and potential policy/tariff risks. **Guidance was qualitative but realistic**, with management signaling that Q4 was in line with internal expectations and that portfolio reshaping should drive future profitability. No specific forward numbers were provided, but capital allocation (notably share repurchases) remains a priority.

---

## Key Risks

- **Cost inflation and margin pressures** from ongoing SG&A and operational expenses.
- **Regulatory and policy risks** (drug pricing, tariffs, international market volatility).
- **Demand-side risks** from academic/biotech funding declines and macroeconomic uncertainty.
- **Execution risk** in realizing expected benefits from the Exosome Diagnostics divestiture.

---

## Expected Market Reaction

Analysts and investors are likely to **focus on the strong adjusted results and strategic portfolio moves**, with initial positive sentiment expected despite the GAAP miss. The market may **underappreciate the near-term margin uplift** and future optionality from retained exosome technology rights, while potentially overemphasizing the impact of one-off charges on GAAP results.

---

## Final Takeaway

**Bio-Techne’s Q4 FY2025 was a strong quarter on an adjusted basis, with clear evidence of margin resilience and strategic focus.** The market may be underestimating the positive impact of the Exosome Diagnostics divestiture and the company’s ability to drive future profitability from its core segments. **Key upcoming catalysts** include the closing of the Exosome Diagnostics transaction and further updates on capital deployment. Investors should monitor execution on portfolio reshaping and external macro risks, but the underlying business remains well-positioned for margin expansion and long-term growth.

Bio-Techne: Portfolio Shift Fuels Margin Upside

Bio-Techne’s Protein Sciences segment remains resilient, but margin compression and macro headwinds are likely to limit near-term upside despite a $500M share buyback program.

# Bio-Techne Corporation: Navigating Macro Headwinds with Protein Sciences Resilience – Q4 2024 Earnings Outlook

## Executive Summary

We maintain a **Neutral** outlook on Bio-Techne Corporation (NASDAQ: TECH) for the upcoming quarter, as the company’s core Protein Sciences segment continues to deliver robust results, but external macro headwinds and operational pressures are likely to temper near-term upside. **Q3 2024 revenue of $316.2M** reflected a trailing 12-month growth rate of **4.2%**, but management now guides for **low single-digit revenue growth** in Q4, citing NIH funding uncertainty and tariff challenges. While the market is focused on topline deceleration, we believe the **$500M share repurchase program** is an underappreciated lever that could support EPS if macro conditions stabilize. The key risk the Street may be underestimating is the potential for **margin compression** if inventory build-up persists and demand softens further.

## Recent Trends Signal What’s Next

Bio-Techne’s recent financial performance points to a measured deceleration in growth, with segment-level resilience offset by macro-driven caution. Over the last four quarters, revenue has grown modestly, but margin trends suggest increasing cost pressures.

### Quarterly Financial Trends Table

| Quarter      | Revenue ($M) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) | EPS   |
|--------------|--------------|------------------|----------------------|---------------|-------|
| Q4 2023      | 309.3        | 68.1             | 12.2                 | 9.8           | 0.54  |
| Q1 2024      | 312.7        | 67.8             | 11.9                 | 9.5           | 0.55  |
| Q2 2024      | 314.9        | 67.5             | 11.5                 | 9.2           | 0.54  |
| Q3 2024      | 316.2        | 67.2             | 11.1                 | 8.9           | 0.56  |

**Trend:** Revenue has increased sequentially, but **operating margin has compressed by 110bps** over the past year, and EPS growth has stalled. This signals that while topline is holding, cost inflation and operational headwinds are eroding profitability—a dynamic likely to persist into Q4.

## Management’s Forward Tone and Positioning

Management’s recent commentary has shifted from confident growth to a more measured, risk-aware stance. In the Q3 2024 earnings call, leadership stated:  
> “We’re seeing early signs of normalization in demand, but it is prudent to be conservative given the current funding environment.”  
This contrasts with the prior quarter’s more optimistic tone, where management emphasized “broad-based momentum across our portfolio.” The current messaging signals a focus on **cost discipline and cautious guidance**, with explicit references to “temporary headwinds” and “external uncertainties.” This pivot suggests investors should expect **modest EPS progress and potential margin compression** in the near term.

## KPI Trends & Upcoming Quarter Drivers

Three KPIs are most relevant for Q4 2024:

- **Inventory Levels:** Inventory increased by **$12M QoQ** in Q3, raising concerns about working capital efficiency and potential write-downs if demand softens.
- **Short Interest:** Short interest rose to **5.28% of float** (up 12% QoQ), indicating rising bearish sentiment.
- **Protein Sciences Revenue:** This segment delivered **$227.7M in Q3** (+6% YoY), and is expected to remain the primary growth engine.

### KPI Movement Table

| KPI                    | Q3 2023 | Q2 2024 | Q3 2024 | YoY Change | QoQ Change |
|------------------------|---------|---------|---------|------------|------------|
| Inventory ($M)         | 98      | 104     | 116     | +18%       | +12%       |
| Short Interest (% float)| 4.2     | 4.7     | 5.28    | +26%       | +12%       |
| Protein Sciences Rev ($M)| 214.8 | 221.3   | 227.7   | +6%        | +3%        |

**Implication:** Elevated inventory and short interest could pressure margins and sentiment, while continued strength in Protein Sciences is likely to anchor revenue.

## Missed by the Street

A key overlooked signal is the **$500M share repurchase authorization** announced in Q3 filings. While consensus is focused on near-term margin and revenue headwinds, this capital allocation move signals management’s confidence in long-term cash flow and balance sheet strength. As stated in the filing:  
> “The share buyback is aimed at enhancing shareholder value.”  
If executed during periods of share price weakness, this could provide a **meaningful EPS tailwind** once macro conditions stabilize.

## Scenarios for the Upcoming Quarter

### Bull / Base / Bear Case Table

| Scenario  | Revenue ($M) | EPS   | Operating Margin (%) | Key Assumptions                                              |
|-----------|--------------|-------|----------------------|--------------------------------------------------------------|
| Bull      | 322          | 0.60  | 11.3                 | Tariff relief, robust Protein Sciences, inventory clears     |
| Base      | 318          | 0.56  | 11.1                 | Low single-digit growth, margin pressure ~100bps             |
| Bear      | 314          | 0.52  | 10.8                 | Persistent macro headwinds, inventory overhang, weak demand  |

**Most Likely:** The **Base case** is most probable, given management’s conservative tone, ongoing macro risks, and recent margin trends. We expect **Q4 revenue of $318M, EPS of $0.56, and operating margin near 11.1%**.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($M) | EPS   | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|-------|------------------|----------------------|
| Q4 2023      | 309.3        | 0.54  | 68.1             | 12.2                 |
| Q1 2024      | 312.7        | 0.55  | 67.8             | 11.9                 |
| Q2 2024      | 314.9        | 0.54  | 67.5             | 11.5                 |
| Q3 2024      | 316.2        | 0.56  | 67.2             | 11.1                 |

### KPI Movement (YoY and QoQ)

| KPI                    | Q3 2023 | Q3 2024 | YoY Change | Q2 2024 | Q3 2024 | QoQ Change |
|------------------------|---------|---------|------------|---------|---------|------------|
| Inventory ($M)         | 98      | 116     | +18%       | 104     | 116     | +12%       |
| Short Interest (% float)| 4.2     | 5.28    | +26%       | 4.7     | 5.28    | +12%       |
| Protein Sciences Rev ($M)| 214.8 | 227.7   | +6%        | 221.3   | 227.7   | +3%        |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand, but it is prudent to be conservative given the current funding environment.”**  
   – Q3 2024 Earnings Call  
   *Signals a shift to cautious guidance and risk management.*

2. **“Temporary headwinds are impacting our near-term outlook, but our long-term growth drivers remain intact.”**  
   – Q3 2024 Earnings Call  
   *Implies confidence in core business, but warns of short-term volatility.*

3. **“We are actively managing inventory levels to align with anticipated demand.”**  
   – Q3 2024 Earnings Call  
   *Highlights operational focus on working capital efficiency.*

4. **“The share buyback is aimed at enhancing shareholder value.”**  
   – Q3 2024 10-Q Filing  
   *Indicates management’s confidence in long-term fundamentals.*

5. **“We expect margin pressure to persist in the coming quarter due to input cost inflation and tariffs.”**  
   – Q3 2024 Earnings Call  
   *Warns of continued profitability headwinds.*

6. **“Recent distribution agreements are expected to contribute to order flow in the second half.”**  
   – Q3 2024 Earnings Call  
   *Points to potential upside from new partnerships.*

7. **“We remain committed to disciplined capital allocation and cost control.”**  
   – Q3 2024 Earnings Call  
   *Reinforces a defensive posture in the current environment.*

---

**In summary:** Bio-Techne’s Q4 2024 outlook is anchored by Protein Sciences resilience, but macro and operational headwinds warrant a cautious stance. The share repurchase program is a potential offset to near-term EPS pressure, but margin compression remains the key risk to watch.

TECH: Margin Pressure Offsets Protein Sciences Strength